Peregrine's corporate office is located in Tustin, California.
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
When was Peregrine founded?
Peregrine was founded in June 3, 1981 under its former name Techniclone International Corporation, a California corporation. On March 24, 1997, Techniclone International Corporation was merged with and into Techniclone Corporation, a corporation incorporated in the State of Delaware on September 25, 1996. This merger was effected for the purpose of effecting a change in the Company's state of incorporation from California to Delaware. The Company changed its name from Techniclone Corporation to Peregrine Pharmaceuticals, Inc. in October 2000.
When and where was Peregrine incorporated?
Peregrine was incorporated in the State of Delaware on September 25, 1996.
Who is Peregrine's outside legal counsel?
Peregrine's outside legal counsel is Snell & Wilmer, LLP.
Snell & Wilmer, L.L.P.
600 Anton Blvd., Ste. 1400
Costa Mesa, CA 92626-7689
Phone: 714-427-7000
Fax: 714-427-7799 www.swlaw.com
Who are Peregrine's independent auditors?
Peregrine's independent auditors are Ernst & Young LLP.
Ernst & Young LLP
18111 Von Karman Avenue, Suite 1000
Irvine, CA 92612
How can I contact Peregrine?
Please refer to our Contact Us page or contact our investor relations directly at (800)987-8256.
When did Peregrine acquire the rights to the VTA technology?
On April 24, 1997, the Company acquired all of the outstanding stock of Vascular Targeting Technologies, Inc. (formerly known as Peregrine Pharmaceuticals, Inc.) in exchange for 5,080,000 shares of the Company's common stock and the assumption of net liabilities of approximately $484,000. Vascular Targeting Technologies, Inc. was a development stage company involved in the research and development of vascular targeting agents. The acquisition was accounted for as a purchase. The excess of the purchase price over net tangible assets acquired (cash and notes receivable) and liabilities assumed (accounts payable and accrued liabilities) represents the difference between the fair value of the Company's common stock exchanged and the fair value of net assets purchased. The excess purchase price of $27,154,402 over the net tangible assets acquired represents the amount paid for acquired technologies and related intangible assets. The excess purchase price for the acquisition had been charged to operations as of the effective date of the acquisition as the related technologies have not reached technological feasibility and the technology had no known future alternative uses other than the possibility for treating cancer patients.
When did Peregrine acquire the rights to the TNT technology?
On January 18, 1994, Peregrine and Cancer Biologics, Inc. ("CBI") entered into an Agreement and Plan of Merger (the "Agreement and Plan of Merger") which contemplated the merger of CBI with and into Peregrine. On June 10, 1994, the shareholders of the Company approved the merger pursuant to the Agreement and Plan of Merger. The merger between CBI and the Company was completed on July 26, 1994. The assets of CBI acquired by the Company consist primarily of research and development of the TNT antibody technology. As a result of the merger, the Company incurred an immediate charge to operations for purchased in-process research and development of approximately $4,850,000. This amount represents the excess of the fair market value of the Company's common stock issued over the net assets acquired of CBI, plus an additional non-recurring charge relating to CBI stock options assumed by the Company.
Do you have another question that hasn't been answered?
Please submit your question using the form below. Fields marked with an * are required.
Investor FAQs 
show all
hide all
